Meeting Information - The company will hold its second extraordinary general meeting of shareholders on July 31, 2025, at 14:00 [1][2] - The meeting will be conducted both in-person and via online voting platforms provided by the Shenzhen Stock Exchange [2][4] - The record date for shareholders eligible to attend the meeting is July 28, 2025, at 15:00 [2][3] Voting Procedures - Shareholders can vote through either the Shenzhen Stock Exchange trading system or the internet voting system, but must choose one method for each voting right [2][5] - The voting code for the meeting is "362252" and the voting abbreviation is "莱士投票" [4][5] - Specific procedures for online voting are detailed in the attachments provided [4][5] Attendance Requirements - Legal representatives of corporate shareholders must present identification and relevant documentation to attend the meeting [3][4] - Individual shareholders must bring their identification and shareholder account card for registration [4] - Remote shareholders can register via email or mail, with a deadline of July 30, 2025, at 16:00 [4] Proposal Details - The meeting will review non-cumulative voting proposals, with the requirement that more than 75% of the voting rights present must agree for proposals to pass [3][5] - If shareholders vote on both the total proposal and specific proposals, the first valid vote will take precedence [5]

证券代码：002252 证券简称：上海莱士 公告编号：2025-051 上海莱士血液制品股份有限公司 关于第六届董事会第十二次（临时）会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）第六届董事会第十二次（临时） 会议于 2025 年 7 月 10 日以电话和邮件方式发出会议通知，并于 2025 年 7 月 15 日 14 点以现场结合通讯方式召开。 本次会议应出席董事 9 名，实际出席董事 9 名。本次会议由公司董事长谭丽 霞女士召集和主持，公司监事、高级管理人员等列席会议。会议的召集召开与表 决程序符合《公司法》和《公司章程》等有关规定。与会董事经过充分研究和讨 论，审议通过了如下议案： 1、审议通过《关于拟聘任 2025 年度会计师事务所的议案》 公司拟聘任安永华明会计师事务所（特殊普通合伙）担任公司 2025 年度会 计师事务所。 表决结果：9 票同意、0 票反对、0 票弃权。 本议案已经公司董事会审计委员会审议通过。本议案尚需提交公司 2025 年 第二次临时股东大会审议。 《关于拟聘任 2025 ...

特别提示： 证券代码：002252 证券简称：上海莱士 公告编号：2025-053 上海莱士血液制品股份有限公司 关于拟聘任2025年度会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 1、拟聘任会计师事务所名称：安永华明会计师事务所（特殊普通合伙） 2、上年度会计师事务所名称：毕马威华振会计师事务所（特殊普通合伙） 3、变更会计师事务所的原因：根据公司业务与未来发展的审计需求，通过 审慎研究和考量，公司拟聘任安永华明会计师事务所（特殊普通合伙）（以下简 称"安永华明"）担任公司2025年度会计师事务所。公司已就变更审计机构的相 关事宜与前、后任会计师也进行了沟通说明，前后任会计师均已知悉本事项且对 本次更换无/未提出异议。 4、本次变更会计师事务所事项符合财政部、国务院国资委、证监会印发的 《国有企业、上市公司选聘会计师事务所管理办法》（财会[2023]4号）的规定。 上海莱士血液制品股份有限公司（"公司"）于2025年7月15日召开了第六届 董事会第十二次（临时）会议及第六届监事会第七次会议，审议通过了《关于拟 聘任2025年度会计师事务 ...

上海莱士 002252 公司章程 上海莱士血液制品股份有限公司 章程 （2025年7月修订） 2025年7月 1 上海莱士 002252 公司章程 上海莱士血液制品股份有限公司 章 程 目 录 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第四章 股东和股东大会 第五章 董事会 第六章 总经理及其他高级管理人员 1 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第一节 股东 第二节 股东大会的一般规定 第三节 股东大会的召集 第四节 股东大会的提案与通知 第五节 股东大会的召开 第六节 股东大会的表决和决议 第一节 董事 第二节 董事会 上海莱士 002252 公司章程 第七章 监事会 第八章 财务会计制度、利润分配和审计 第九章 通知与公告 第十章 合并、分立、增资、减资、解散和清算 第十一章 修改章程 第十二章 附则 2 第一节 监事 第二节 监事会 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第一节 通知 第二节 公告 第一节 合并、分立、增资和减资 第二节 解散和清算 英文名称：Shanghai RAAS Blood Products Co., Ltd. 第 ...

证券代码：002252 证券简称：上海莱士 公告编号：2025-054 上海莱士血液制品股份有限公司 4、会议召开的日期、时间： 现场会议召开时间为：2025 年 7 月 31 日（星期四）14:00； 网络投票时间为：2025 年 7 月 31 日（星期四）； 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 7 月 31 日（星期四）的交易时间，即 9:15－9:25，9:30－11:30，13:00－15:00；通 过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 7 月 31 日（星期 四）9:15 至 15:00 期间的任意时间。 关于召开2025年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）于2025年7月15日召开第六届董 事会第十二次（临时）会议，审议通过了《关于召集2025年第二次临时股东大会 的议案》，会议定于2025年7月31日（星期四）14:00召开公司2025年第二次临时股 东大会，现将本次股东大会的有关事项通知如下： 一、召开会议 ...

证券代码：002252 证券简称：上海莱士 公告编号：2025-052 上海莱士血液制品股份有限公司 关于第六届监事会第七次会议决议的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）第六届监事会第七次会议于 2025 年 7 月 10 日以电子邮件和电话方式发出通知，并于 2025 年 7 月 15 日下午 3 点 以现场方式召开。 会议应出席监事 3 名，实际出席监事 3 名。本次会议由监事会主席张吉女士 召集和主持。会议的召集召开与表决程序符合《公司法》和《公司章程》的有关 规定。与会监事经过充分研究和讨论，审议并通过了如下议案： 1、《关于拟聘任 2025 年度会计师事务所的议案》 经审核，监事会认为：安永华明会计师事务所（特殊普通合伙）具备必要的 资质和独立性，具备相应的经验与能力，能够满足公司未来审计工作的需求，本 次聘任会计师事务所有充分和合理的理由。公司本次聘任会计师事务所的程序符 合相关法律、法规规定。公司监事会同意聘任安永华明会计师事务所（特殊普通 合伙）担任公司 2025 年度会计师事务所，并同 ...

Group 1 - Regulatory authorities have set clear requirements for listed companies' market value management, prompting companies like Hualan Biological to implement a market value management system [1] - Hualan Biological plans to conduct mergers and acquisitions to enhance its core competitiveness and expand its business scope [1] Group 2 - The blood products industry in China has evolved due to the strategic layout of state-owned enterprises, flexible adjustments by private enterprises, and the exit of foreign capital, leading to a competitive landscape dominated by major players like China National Biological Group, Taibang Biological, Hualan Biological, and Shanghai Raas [2] - Hualan Biological became the only blood product company in China to achieve a thousand-ton plasma volume through internal operations, significantly increasing its market position through a series of acquisitions from 2004 to 2007 [2] Group 3 - Hualan Biological has implemented various measures to enhance plasma collection, achieving a record plasma collection volume of 1586.37 tons in 2024, ranking third among blood product companies [3] Group 4 - The blood products industry has high entry barriers, with stringent regulations on plasma collection and production, which necessitates a higher level of technical and financial capability [4] - The consolidation of the industry is expected to improve regulatory compliance and overall safety, aligning with government policies promoting mergers and acquisitions [4] Group 5 - The number of single plasma collection stations and their collection volume are critical indicators of management efficiency in blood product companies, with future mergers likely to focus on quality rather than mere expansion [5] - The blood products industry is anticipated to undergo a restructuring phase, with a shift from expansion to quality improvement, emphasizing innovation and operational efficiency as key competitive factors [5]

Group 1 - The medical health ETF Taikang (159760) has seen a 0.17% increase, marking its fifth consecutive rise, while the index it tracks, the National Certificate Public Health and Medical Health Index (980016), rose by 0.13% [1] - As of July 14, the latest scale of the medical health ETF Taikang reached 82.4979 million yuan, a new high in nearly three months [2] - The medical device sector is expected to experience a performance turning point, driven by policies such as the old-for-new program and the gradual clearance of channel inventory [2] Group 2 - The top ten weighted stocks in the National Certificate Public Health and Medical Health Index account for 51.67% of the index, with leading companies including WuXi AppTec (603259) and Hengrui Medicine (600276) [3] - The CDMO sector has rebounded, with WuXi AppTec expected to see significant growth in revenue and profit by mid-2025, indicating strong global market demand [2] - The innovation drug industry chain is anticipated to enter a new upward cycle, supported by an improving domestic investment environment and active financing activities [2]

Core Viewpoint - The pharmaceutical sector is experiencing a surge in sentiment due to the strong performance of leading CXO companies, leading to significant increases in related ETFs in both A-shares and Hong Kong stocks [1][2]. Group 1: CXO Company Performance - WuXi AppTec expects to achieve revenue of approximately 20.8 billion yuan in the first half of 2025, representing a year-on-year growth of about 20.64% [2]. - The net profit attributable to shareholders is projected to be around 8.56 billion yuan, showing a year-on-year increase of approximately 101.92% [2]. - The adjusted net profit is expected to be about 6.31 billion yuan, reflecting a year-on-year growth of approximately 44.43% [2]. - The company continues to focus on its unique "integrated, end-to-end" CRDMO business model, expanding new capabilities and optimizing production processes [2]. Group 2: Market Trends and Investment Sentiment - The global healthcare investment and financing amount is showing signs of recovery, with a projected growth rate of 25.3% in total financing for 2024 [2]. - The recovery in orders for CXO services is evident, with major companies reporting significant increases in their order backlogs [5][6]. - The trend of Chinese innovative drugs going global is gaining recognition in the capital market, indicating a strong future for the industry [6]. Group 3: ETF Performance - The Biopharmaceutical ETF (159839) has seen a rise of over 2%, with significant inflows for three consecutive days [1]. - The Hang Seng Biotechnology ETF (513280) increased by 1.5%, marking it as the only ETF tracking the Hang Seng Biotechnology Index to receive net inflows this year [7]. - The Biopharmaceutical ETF focuses on industry leaders, enhancing its potential for higher returns and volatility [7].

Core Insights - Human fibrinogen is recognized globally for its clinical application value in regulating coagulation function, with increasing demand driven by aging populations and rising living standards [1][13] - The market size for human fibrinogen in China is projected to grow from 1.529 billion yuan in 2021 to 2.15 billion yuan in 2024, reflecting a compound annual growth rate (CAGR) of 12.0% [1][13] - The production process of human fibrinogen is expected to improve with technological advancements, leading to enhanced product quality and continuous market growth [1][13] Industry Overview - Fibrinogen is a key substrate in the coagulation and hemostasis process, essential for maintaining normal coagulation and promoting platelet aggregation [3] - Human fibrinogen is derived from healthy human plasma, processed to remove viruses, and is used as an effective replacement therapy for fibrinogen deficiency [3] - The normal concentration of fibrinogen in the human body is maintained at 2-4 g/L, and it is crucial for correcting hypofibrinogenemia and improving coagulation disorders [3] Market Dynamics - The number of blood collection stations and plasmapheresis stations in China is increasing, with 3 new stations approved and 17 new operational stations in 2024, leading to a steady rise in plasma collection [8] - The total plasma collection volume in 2024 is expected to reach 13,400 tons, a year-on-year increase of 10.94%, with major companies like Tian Tan Biological, Taibang Biological, and Shanghai Raist accounting for approximately 80% of the domestic plasma collection [8] - The growth in the number of medical institutions, driven by an aging population and increased health awareness, is expected to boost the demand for human fibrinogen [11] Competitive Landscape - The human fibrinogen industry is attracting significant attention from capital markets, with increasing competition as more companies enter the field [17] - Key players in the industry include Huaren Boya Biological Pharmaceutical Group, Shanghai Raist Blood Products, and Beijing Tiantan Biological Products, among others [17][18] Future Trends - Continuous government policy support is expected to benefit the human fibrinogen market, with initiatives aimed at improving the quality and safety of blood products [22] - Companies are focusing on optimizing production processes and enhancing plasma utilization rates, which will drive overall industry progress [23] - The expansion of medical insurance coverage and rising consumer spending on healthcare are anticipated to gradually increase the market demand for human fibrinogen [24]